GlassScriptPhysician profile
Sandeep Sharma
NPI 1225332133
$10,592.88
in general payments reported to CMS, 2019-2025
18 companies · $326 in 2025
The $326 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.42 · 2022: $225 · 2023: $606 · 2024: $9,373 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,500 · Food and Beverage: $1,579 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,500.00 |
| Food and Beverage | $1,578.67 |
| Travel and Lodging | $226.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,743.45 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $344.62 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.11 | 2021-2025 | Ofev, Stiolto Respimat |
| Grifols USA, LLC | $280.06 | 2022-2025 | Prolastin-C Liquid |
| Insmed, INC. | $139.07 | 2023-2025 | Arikayce, Brinsupri |
| Amgen INC. | $123.48 | 2023 | Tezspire |
| Glaxosmithkline, LLC. | $104.98 | 2022-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $96.74 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $79.88 | 2023 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $72.11 | 2022-2025 | Glassia, Aralast |
| Regeneron Healthcare Solutions, INC. | $65.86 | 2024-2025 | Dupixent |
| Baxter Healthcare | $64.03 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $62.88 | 2021-2025 | Zerbaxa |
| Philips North America LLC | $48.61 | 2022-2024 | (Ak6) Vest Therapy |
| Genentech USA, INC. | $31.48 | 2022-2023 | Xolair |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.58 | 2024 | Enhertu |
| Siemens Medical Solutions USA, INC. | $18.16 | 2024 | Cios Spin |
| Mallinckrodt Hospital Products INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.